Pfizer’s Vydura recommended by NICE for acute migraines
The treatment is the first oral GPCR receptor antagonist class recommended for NHS use
Read Moreby Jen Brogan | Sep 18, 2023 | News | 0
The treatment is the first oral GPCR receptor antagonist class recommended for NHS use
Read Moreby Jen Brogan | Sep 18, 2023 | News | 0
The updated vaccines more closely target current circulating variants
Read Moreby Jen Brogan | Aug 25, 2023 | News | 0
The decision follows a recent recommendation from the European Medicines Agency’s human medicines committee
Read Moreby Jen Brogan | Aug 23, 2023 | News | 0
The decision allows Abrysvo to be given to those who are 32 to 36 weeks into their pregnancy
Read Moreby Jen Brogan | Jun 2, 2023 | News | 0
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
Read Moreby John Pinching | May 10, 2023 | News | 0
Patients living with the debilitating impacts of migraine attacks will be able to access Vydura
Read Moreby John Pinching | Mar 21, 2023 | News | 0
Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer
Read Moreby John Pinching | Feb 17, 2023 | News | 0
Research concerning candidate VLA15 has been discontinued across certain trial sites
Read Moreby John Pinching | Dec 16, 2022 | News | 0
Partnership will support development of new algorithm and identify at risk patients
Read Moreby John Pinching | Dec 1, 2022 | News | 0
Children and adults have been treated using the Lyme disease antibody candidate VLA15
Read Moreby John Pinching | Nov 17, 2022 | News | 0
Therapy will be available on the NHS as a clinical treatment option for adults with COVID-19
Read Moreby Emily Kimber | Aug 26, 2022 | News | 0
It is estimated that RSV infections in older adults account for 177,000 hospitalisations and 14,000 deaths each year in the US alone
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479